Premium
Randomized trial of 5‐fluorouracil and mitomycin C with or without streptozotocin for advanced pancreatic cancer. A Southwest oncology group study
Author(s) -
Bukowski Ronald M.,
Balcerzak Stanley P.,
O'Bryan Robert M.,
Bonnet John D.,
Chen T. Timothy
Publication year - 1983
Publication title -
cancer
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 3.052
H-Index - 304
eISSN - 1097-0142
pISSN - 0008-543X
DOI - 10.1002/1097-0142(19831101)52:9<1577::aid-cncr2820520906>3.0.co;2-8
Subject(s) - medicine , fluorouracil , mitomycin c , randomized controlled trial , oncology , streptozotocin , cancer , pancreatic cancer , diabetes mellitus , surgery , endocrinology
A prospective randomized trial comparing streptozotocin, mitomycin C, and 5‐FU (SMF) with mitomycin C and 5‐FU (MF) in patients with advanced pancreatic cancer was performed. In patients with measurable disease the response rates were 34% (19/56) to SMF, and 8% (5/60) to MF ( P = 0.009). Median survivals were similar, however, 18 versus 17 weeks ( P = 0.356). Median survival of patients responding to chemotherapy was 33 weeks, and for nonresponders it was 17 weeks ( P = 0.002). In patients with nonmeasurable disease, median survivals were 21 weeks (SMF) and 18 weeks (MF) ( P = 0.797). Patients surviving ⩾48 weeks, however, appeared to be increased in the SMF arm (14 patients) compared to the MF (7 patients). Toxicity was moderate for both regimens, with SMF having greater gastrointestinal and renal toxicity. Chemotherapy with SMF appears to produce objective responses in patients with pancreatic cancer, but does not improve survival compared to MF.